IMUGENE LIMITED — Investor Presentation 2017

Nov 13, 2017

ASX:IMU

Immuno Oncology: Trends and Developments on The Horizon

Christoph Zielinski

Comprehensive Cancer Center and Vienna Cancer Center Medical Univ. Vienna – General Hospital Central European Cooperative Oncology Group (CECOG)

==> picture [720 x 134] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Basics of Immune Checkpoint Inhibitor Treatment of Cancer

Video

http://players.brightcove.net/2696240571001/VyQDdgBTl_default/index.html?videoId=5230623752001

==> picture [720 x 136] intentionally omitted <==

----- Start of picture text -----

v
----- End of picture text -----

==> picture [720 x 134] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

==> picture [661 x 376] intentionally omitted <==

----- Start of picture text -----

v
----- End of picture text -----

3

New Approaches to Build on Active Immunotherapies to Maximize Clinical Benefit

==> picture [720 x 135] intentionally omitted <==

----- Start of picture text -----

Plus Plus
chemotherapy radiotherapy
Active
immunotherapy
----- End of picture text -----

Plus other immunotherapy

Drake CG. Ann Oncol . 2012;23(suppl 8):viii41–viii46; Hannani D, et al. Cancer J. 2011;17:351–358; Ménard C, et al. Cancer Immunol Immunother . 2008;57:1579–1587; Ribas A, et al. Curr Opin Immunol . 2013:25:291–296.

==> picture [11 x 14] intentionally omitted <==

----- Start of picture text -----

4
----- End of picture text -----

Immuno Oncology: Examples of Partners for Combination > 2017

• Combination Checkpoint Blockade

• Checkpoint-Blockade plus

• Immune-Stimulatory Agents

• Metabolic Modulators

• Other Immune Modulators

• • Macrophage Inhibitors

• • Injectable Therapies

• • Cancer Vaccines

• Adoptive Cell Transfer

==> picture [11 x 14] intentionally omitted <==

----- Start of picture text -----

5
----- End of picture text -----

Combination of Immune Checkpoint Inhibition and Vaccines

==> picture [720 x 438] intentionally omitted <==

----- Start of picture text -----

v
6
----- End of picture text -----

Immuno Oncology

• Revolutionary Change in Treatment Paradigm of Malignancies

• v

• v

• • Currently, we are witnessing ONLY the End of the Beginning

==> picture [720 x 134] intentionally omitted <==

----- Start of picture text -----

7
----- End of picture text -----

==> picture [720 x 135] intentionally omitted <==

----- Start of picture text -----

ASX:IMU
----- End of picture text -----

The future of vaccines against cancer

Univ. Prof. Dr. Ursula Wiedermann Institute of Specific Prophylaxis & Tropical Medicine Medical University of Vienna, Austria, Europe

==> picture [9 x 9] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Why go for Active Immunization against cancer ?

Difference between passive immunotherapy and active vaccination

==> picture [186 x 150] intentionally omitted <==

==> picture [720 x 136] intentionally omitted <==

----- Start of picture text -----

v
----- End of picture text -----

2

==> picture [173 x 37] intentionally omitted <==

Action of monoclonal antibodies Herceptin and/or Perjeta

==> picture [308 x 138] intentionally omitted <==

Binding site of Binding site of

Tumor cell

HER-Vaxx: Vaccine better than monoclonal antibodies

• Advanced B-cell vaccine designed to stimulate a patient’s own immune system to repeatedly attack the cancer

• Stimulates a patient’s B cells to produce polyclonal antibodies that target cells with overexpressing HER-2 receptors on their surface

• HER-Vaxx consists (1) of three fused peptides from the HER-2 receptor conjugated to (2) a carrier plus (3) an adjuvant

==> picture [720 x 269] intentionally omitted <==

----- Start of picture text -----

v
2. P6 3.
1.
Computer aided Enhanced Enhanced
alogorithms immunogenicity Ab titers
P4 P4
Epitopes Epitopes
Add adjuvant
P6 Identified Fused
P7 P7
carrier
----- End of picture text -----

HER-Vaxx: Mechanism Of Action

==> picture [720 x 451] intentionally omitted <==

----- Start of picture text -----

Long lasting immune response
P6 3 Peptides because of memory !!
P4 Tumor
P7 HER-Vaxx Cell
Antibody Secretion
HER-2/neu
v
B-cell
Activation
Via helper T-cells
HER-Vaxx B-Cell
Immunotherapy
----- End of picture text -----

Immune-checkpoint antibodies combined with cancer vaccines

PD-1 : Programmed cell Death 1 PD-L1 : PD-1 ligand

CTLA-4 etc.

==> picture [720 x 136] intentionally omitted <==

----- Start of picture text -----

v
----- End of picture text -----

==> picture [720 x 134] intentionally omitted <==

Combination of Immune Checkpoint Inhibition and Vaccines

==> picture [720 x 438] intentionally omitted <==

----- Start of picture text -----

v
7
----- End of picture text -----

HerVaxx and PD1 monoclonal antibody leads to enhanced anti-Her-2 responses at the cellular level

IL-2 production

IL-5 production

==> picture [720 x 136] intentionally omitted <==

----- Start of picture text -----

v
----- End of picture text -----

8

Identification of Mimotope – Vaccine candiates

==> picture [720 x 428] intentionally omitted <==

----- Start of picture text -----

v
Peptides + Carrier
Selection of Defined
peptide mimotopes aminoacid
sequence
Screening
----- End of picture text -----

Mimotope Plattform for generation of vaccine candidates of interest

Generation and use of library with overlapping bio-peptides Screening for positive clones ( E. coli) using the corresponding mAb Retrieving the sequence of the peptide (i.e. mimotope) v Examining the solubility of the identified mimotope Purification of the identified mimotope Specific characterization of the purified mimotope (mimicry or inhibition ELISA) Production of vaccine formulation and Immunization studies

R&D Team at the Medical University of Vienna

v Thank you for your attention !

==> picture [720 x 134] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----